Yi An
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yi An has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Longgang Hu
Department of Cardiology, Affiliated Hospital of Qingdao University, Qingdao, China
3 shared publicationsHua Wang
Department of Cardiology, Affiliated Yantai Yuhuangding Hospital of Qingdao University, Qingdao University, Yantai, China
2 shared publicationsJiaqi Han
Department of medicine, Qingdao University
2 shared publicationsLin Zhong
Department of Cardiology, Affiliated Yantai Yuhuangding Hospital of Qingdao University, Qingdao University, Yantai, China
2 shared publicationsLiu-Dong Li
Department of Cardiology, Affiliated Yantai Yuhuangding Hospital of Qingdao University, Qingdao University, Yantai, China
2 shared publicationsMan Wang
Institute for Translation Medicine, Medical College, Qingdao University, Qingdao, China
2 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1961494
Association of C-reactive protein–triglyceride–glucose index with coronary microvascular dysfunction in patients without obstructive coronary artery disease
Background: Patients with angina symptoms and no obstructive coronary lesions may have coronary microvascular dysfunction (CMD). The C–reactive protein–triglyceride–glucose index(CTI) is a novel metabolic-inflammatory marker, but its value in CMD remains unclear. This study aimed to evaluate the association of metabolic indices with CMD and determine the incremental value of CTI compared with other metabolic indices. Methods: This retrospective cohort study included 129 patients without obstructive coronary artery disease who underwent stress echocardiography after coronary angiography. The associations of CTI, triglyceride–glucose (TyG) index, TyG–Body mass index (TyG–BMI), remnant cholesterol–inflammation index (RCII), and metabolic score for insulin resistance (METS–IR) with CMD were evaluated using correlation analyses and multivariable logistic regression models. ROC curve analysis and DeLong tests were performed to compare predictive performance among metabolic indices, while restricted cubic spline analyses and subgroup analyses were conducted to assess dose–response relationships and the robustness of the associations. Results: Among 129 patients, 64 (49.6%) had CMD. CTI was negatively correlated with coronary flow reserve ( r = −0.490, P < 0.001) and remained independently associated with CMD after multivariable adjustment (OR: 2.472, 95% CI: 1.480–4.128). CTI showed the best predictive performance among the evaluated metabolic indices (AUC: 0.730, 95% CI: 0.644–0.817), with significant improvement in risk classification (NRI = 0.541, P = 0.010). Higher CTI levels were associated with increased CMD prevalence, and the association remained consistent across most subgroups. Conclusion: CTI is strongly associated with CMD and provides incremental value for CMD risk stratification beyond conventional metabolic indices. CTI may serve as a promising metabolic-inflammatory biomarker for identifying individuals with CMD.
- 2 November 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1961494
Open AccessAssociation of C-reactive protein–triglyceride–glucose index with coronary microvascular dysfunction in patients without obstructive coronary artery disease
Background: Patients with angina symptoms and no obstructive coronary lesions may have coronary microvascular dysfunction (CMD). The C–reactive protein–triglyceride–glucose index(CTI) is a novel metabolic-inflammatory marker, but its value in CMD remains unclear. This study aimed to evaluate the association of metabolic indices with CMD and determine the incremental value of CTI compared with other metabolic indices. Methods: This retrospective cohort study included 129 patients without obstructive coronary artery disease who underwent stress echocardiography after coronary angiography. The associations of CTI, triglyceride–glucose (TyG) index, TyG–Body mass index (TyG–BMI), remnant cholesterol–inflammation index (RCII), and metabolic score for insulin resistance (METS–IR) with CMD were evaluated using correlation analyses and multivariable logistic regression models. ROC curve analysis and DeLong tests were performed to compare predictive performance among metabolic indices, while restricted cubic spline analyses and subgroup analyses were conducted to assess dose–response relationships and the robustness of the associations. Results: Among 129 patients, 64 (49.6%) had CMD. CTI was negatively correlated with coronary flow reserve ( r = −0.490, P < 0.001) and remained independently associated with CMD after multivariable adjustment (OR: 2.472, 95% CI: 1.480–4.128). CTI showed the best predictive performance among the evaluated metabolic indices (AUC: 0.730, 95% CI: 0.644–0.817), with significant improvement in risk classification (NRI = 0.541, P = 0.010). Higher CTI levels were associated with increased CMD prevalence, and the association remained consistent across most subgroups. Conclusion: CTI is strongly associated with CMD and provides incremental value for CMD risk stratification beyond conventional metabolic indices. CTI may serve as a promising metabolic-inflammatory biomarker for identifying individuals with CMD.
- 1 August 2021
- Published by Elsevier in Pathology - Research and Practice
- Vol. 224, 153091
MiR-135a-5p inhibits vascular smooth muscle cells proliferation and migration by inactivating FOXO1 and JAK2 signaling pathway
- 1 August 2021
- Published by Elsevier in Pathology - Research and Practice
- Vol. 224, 153091
MiR-135a-5p inhibits vascular smooth muscle cells proliferation and migration by inactivating FOXO1 and JAK2 signaling pathway
- 28 November 2020
- Published by International Heart Journal (Japanese Heart Journal) in International Heart Journal
- Vol. 61 (6) , 1258-1269
MiR-324/SOCS3 Axis Protects Against Hypoxia/Reoxygenation-Induced Cardiomyocyte Injury and Regulates Myocardial Ischemia via TNF/NF-κB Signaling Pathway
We aimed at exploring the function of microRNA-324/cytokine signaling 3 (miR-324/SOCS3) axis in hypoxia/reoxygenation (H/R) -induced cardiomyocyte injury and its underlying mechanism. The differential expression genes were analyzed based on the GSE83500 and GSE48060 datasets from the Gene Expression Omnibus (GEO) database. Then, to conduct the function enrichment analysis, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases were used. The upstream regulatory microRNAs (miRNAs) of the identified genes were predicted by miRanda, miRWalk, and TargetScan websites. MiR-324 expression was measured with quantitative real-time polymerase chain reaction (qRT-PCR). The target binding of miR-324 and SOCS3 was established by dual-luciferase reporter assay. Cardiomyocyte proliferation was analyzed by cell counting kit-8 (CCK-8) assay, whereas the apoptosis was investigated via flow cytometry. The expression of TNF pathway-related proteins was detected by western blot analysis. SOCS3 was upregulated in patients with myocardial infarction (MI), and function enrichment analyses proved that SOCS3 was enriched in TNF signaling pathway. Moreover, we found that miR-324 was the upstream regulatory miRNA of SOCS3 and negatively regulated SOCS3 expression. MiR-324 was downregulated in cardiomyocytes with H/R-induced injury, inhibiting cell proliferation. In the H/R model, SOCS3 suppresses cardiomyocyte proliferation, which was recovered by miR-324, and induces cell apoptosis, which was repressed by miR-324 via regulating the expression of cleaved caspase-3 and p P38-MAPK. MiR-324 upregulation decreased the protein levels of TNF-α, p-P65, and p-IκBα in cardiomyocytes that suffered from H/R, which was reversed with SOCS3 overexpression. MiR-324/SOCS3 axis could improve the H/R-induced injury of cardiomyocytes via regulating TNF/NF-κB signaling pathway, and this might provide a new therapy strategy for myocardial ischemia.
- 28 November 2020
- Published by International Heart Journal (Japanese Heart Journal) in International Heart Journal
- Vol. 61 (6) , 1258-1269
MiR-324/SOCS3 Axis Protects Against Hypoxia/Reoxygenation-Induced Cardiomyocyte Injury and Regulates Myocardial Ischemia via TNF/NF-κB Signaling Pathway
We aimed at exploring the function of microRNA-324/cytokine signaling 3 (miR-324/SOCS3) axis in hypoxia/reoxygenation (H/R) -induced cardiomyocyte injury and its underlying mechanism. The differential expression genes were analyzed based on the GSE83500 and GSE48060 datasets from the Gene Expression Omnibus (GEO) database. Then, to conduct the function enrichment analysis, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases were used. The upstream regulatory microRNAs (miRNAs) of the identified genes were predicted by miRanda, miRWalk, and TargetScan websites. MiR-324 expression was measured with quantitative real-time polymerase chain reaction (qRT-PCR). The target binding of miR-324 and SOCS3 was established by dual-luciferase reporter assay. Cardiomyocyte proliferation was analyzed by cell counting kit-8 (CCK-8) assay, whereas the apoptosis was investigated via flow cytometry. The expression of TNF pathway-related proteins was detected by western blot analysis. SOCS3 was upregulated in patients with myocardial infarction (MI), and function enrichment analyses proved that SOCS3 was enriched in TNF signaling pathway. Moreover, we found that miR-324 was the upstream regulatory miRNA of SOCS3 and negatively regulated SOCS3 expression. MiR-324 was downregulated in cardiomyocytes with H/R-induced injury, inhibiting cell proliferation. In the H/R model, SOCS3 suppresses cardiomyocyte proliferation, which was recovered by miR-324, and induces cell apoptosis, which was repressed by miR-324 via regulating the expression of cleaved caspase-3 and p P38-MAPK. MiR-324 upregulation decreased the protein levels of TNF-α, p-P65, and p-IκBα in cardiomyocytes that suffered from H/R, which was reversed with SOCS3 overexpression. MiR-324/SOCS3 axis could improve the H/R-induced injury of cardiomyocytes via regulating TNF/NF-κB signaling pathway, and this might provide a new therapy strategy for myocardial ischemia.
- Open Access
- 9 October 2020
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 20 (1) , 1-10
Plasma calprotectin was associated with platelet activation and no-reflow phenomenon in acute coronary syndrome
Background: No-reflow occurs in 3–4% of all percutaneous coronary interventions (PCIs) and has a strong negative impact on clinical outcomes of acute coronary syndrome (ACS). Therefore, the discovery of a biomarker that can early predict the occurrence of no-reflow has great clinical significance. Multiple factors including platelet activation are relevant to no-reflow. Calprotectin is found to be a biomarker of plaque instability and is identified to be a novel diagnostic and prognostic biomarker of cardiovascular diseases. The association of plasma calprotectin with platelet activation and no-reflow phenomenon in ACS is not clear. Methods: In this prospective study performed at Yantai Yuhuangding Hospital from 2017 to 2018, a total of 176 Chinese patients with ACS who had undergone PCIs were recruited consecutively, aged from 30 to 88 years. Angiographic no-reflow was defined as thrombolysis in myocardial infarction grade less than 3. Blood samples were collected immediately at admission for the detection of plasma calprotectin and platelet–monocyte aggregates formation. Statistical analysis was performed for the variable’s comparisons between groups and the prediction value of plasma calprotectin for no-reflow. Results: The mean age of the 176 included ACS patients were 64(±11) years and acute ST-segment elevation myocardial infarction (STEMI) was present in 41.5% of patients. Twenty-two patients had no-reflow during the PCI procedures and the prevalence was 12.5%. Patients with higher plasma calprotectin had a higher level of platelet–monocyte aggregates (PMA) and a higher prevalence of no-reflow (p < 0.001). The multivariate regression showed that plasma calprotectin and admission hs-cTnI were independently associated with PMA, while plasma calprotectin and serum LDL-c were independent predictors of no-reflow (p < 0.001 and p = 0.017). AUC of calprotectin for predicting no-reflow were 0.898. The cut-off value of plasma calprotectin for no-reflow was 4748.77 ng/mL with a sensitivity of 0.95 and a specificity of 0.77. Conclusion: Plasma calprotectin was associated with platelet activation and may act as an early predictive biomarker of no-reflow in patients with acute coronary syndrome.
- 9 October 2020
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 20 (1) , 1-10
Open AccessPlasma calprotectin was associated with platelet activation and no-reflow phenomenon in acute coronary syndrome
Background: No-reflow occurs in 3–4% of all percutaneous coronary interventions (PCIs) and has a strong negative impact on clinical outcomes of acute coronary syndrome (ACS). Therefore, the discovery of a biomarker that can early predict the occurrence of no-reflow has great clinical significance. Multiple factors including platelet activation are relevant to no-reflow. Calprotectin is found to be a biomarker of plaque instability and is identified to be a novel diagnostic and prognostic biomarker of cardiovascular diseases. The association of plasma calprotectin with platelet activation and no-reflow phenomenon in ACS is not clear. Methods: In this prospective study performed at Yantai Yuhuangding Hospital from 2017 to 2018, a total of 176 Chinese patients with ACS who had undergone PCIs were recruited consecutively, aged from 30 to 88 years. Angiographic no-reflow was defined as thrombolysis in myocardial infarction grade less than 3. Blood samples were collected immediately at admission for the detection of plasma calprotectin and platelet–monocyte aggregates formation. Statistical analysis was performed for the variable’s comparisons between groups and the prediction value of plasma calprotectin for no-reflow. Results: The mean age of the 176 included ACS patients were 64(±11) years and acute ST-segment elevation myocardial infarction (STEMI) was present in 41.5% of patients. Twenty-two patients had no-reflow during the PCI procedures and the prevalence was 12.5%. Patients with higher plasma calprotectin had a higher level of platelet–monocyte aggregates (PMA) and a higher prevalence of no-reflow (p < 0.001). The multivariate regression showed that plasma calprotectin and admission hs-cTnI were independently associated with PMA, while plasma calprotectin and serum LDL-c were independent predictors of no-reflow (p < 0.001 and p = 0.017). AUC of calprotectin for predicting no-reflow were 0.898. The cut-off value of plasma calprotectin for no-reflow was 4748.77 ng/mL with a sensitivity of 0.95 and a specificity of 0.77. Conclusion: Plasma calprotectin was associated with platelet activation and may act as an early predictive biomarker of no-reflow in patients with acute coronary syndrome.
- Open Access
- 29 August 2020
- Published by Springer Nature in Research Square
Plasma calprotectin was associated with platelet activation and no-reflow phenomenon in acute coronary syndrome
Background No-reflow occurs in 3–4% of all percutaneous coronary interventions (PCIs) and has a strong negative impact on clinical outcomes of acute coronary syndrome. (ACS). Therefore, the discovery of a biomarker that can early predict the occurrence of no-reflow has great clinical significance. Multiple factors including platelet activation are relevant to no-reflow. Calprotectin is found to be a biomarker of plaque instability and is identified to be a novel diagnostic and prognostic biomarker of cardiovascular diseases. But theThe association of plasma calprotectin with platelet activation and no-reflow phenomenon in acute coronary syndromeACS is not clear. Methods In this prospective study performed at Yantai Yuhuangding Hospital from 2017 to 2018, a total of 176 Chinese patients with acute coronary syndromeACS who had undergone percutaneous coronary interventionsPCIs were recruited consecutively, aged from 30 to 88 years. The coronary angiography and percutaneous coronary intervention procedures were performed and angiographicAngiographic no-reflow was defined as a thrombolysis in myocardial infarction scores grade less than 3. Blood samples were collected immediately at admission for the detection of plasma calprotectin and platelet–monocyte aggregates formation. Statistical analysis was performed for the variable’s comparisons between groups and for the prediction value of plasma calprotectin for no-reflow.Results In this study, we have demonstrated that acute coronary syndromeThe mean age of the 176 included ACS patients were 64(±11) years and acute ST-segment elevation myocardial infarction (STEMI) was present in 41.5 percent of patients. 22 patients had no-reflow during the PCI procedures and the prevalence was 12.5%. Patients with higher plasma calprotectin had an elevateda higher level of platelet activation–monocyte aggregates (PMA) and a higher incidenceprevalence of no-reflow. Plasma (p<0.001). The multivariate regression showed that plasma calprotectin level wasand admission hs-cTnI were independently associated with platelet activation and no-reflow in patients with acute coronary syndrome. Despite that platelet activation biomarker platelet–monocyte aggregate was associated with no-flow, onlyPMA, while plasma calprotectin and serum low density lipoprotein cholesterol acted asLDL-c were independent predictors of no-reflow in patients with acute coronary syndrome.(p<0.001 and p=0.017). AUC of calprotectin for predicting no-reflow were 0.898. The cut-off value of plasma calprotectin for no-reflow was 4748.77 ng/mL with a sensitivity of 0.95 and a specificity of 0.77. Conclusion Plasma calprotectin was associated with platelet activation and may act as an early predictionpredictive biomarker of no-reflow in patients with acute coronary syndrome.
- 29 August 2020
- Published by Springer Nature in Research Square
Open AccessPlasma calprotectin was associated with platelet activation and no-reflow phenomenon in acute coronary syndrome
Background No-reflow occurs in 3–4% of all percutaneous coronary interventions (PCIs) and has a strong negative impact on clinical outcomes of acute coronary syndrome. (ACS). Therefore, the discovery of a biomarker that can early predict the occurrence of no-reflow has great clinical significance. Multiple factors including platelet activation are relevant to no-reflow. Calprotectin is found to be a biomarker of plaque instability and is identified to be a novel diagnostic and prognostic biomarker of cardiovascular diseases. But theThe association of plasma calprotectin with platelet activation and no-reflow phenomenon in acute coronary syndromeACS is not clear. Methods In this prospective study performed at Yantai Yuhuangding Hospital from 2017 to 2018, a total of 176 Chinese patients with acute coronary syndromeACS who had undergone percutaneous coronary interventionsPCIs were recruited consecutively, aged from 30 to 88 years. The coronary angiography and percutaneous coronary intervention procedures were performed and angiographicAngiographic no-reflow was defined as a thrombolysis in myocardial infarction scores grade less than 3. Blood samples were collected immediately at admission for the detection of plasma calprotectin and platelet–monocyte aggregates formation. Statistical analysis was performed for the variable’s comparisons between groups and for the prediction value of plasma calprotectin for no-reflow.Results In this study, we have demonstrated that acute coronary syndromeThe mean age of the 176 included ACS patients were 64(±11) years and acute ST-segment elevation myocardial infarction (STEMI) was present in 41.5 percent of patients. 22 patients had no-reflow during the PCI procedures and the prevalence was 12.5%. Patients with higher plasma calprotectin had an elevateda higher level of platelet activation–monocyte aggregates (PMA) and a higher incidenceprevalence of no-reflow. Plasma (p<0.001). The multivariate regression showed that plasma calprotectin level wasand admission hs-cTnI were independently associated with platelet activation and no-reflow in patients with acute coronary syndrome. Despite that platelet activation biomarker platelet–monocyte aggregate was associated with no-flow, onlyPMA, while plasma calprotectin and serum low density lipoprotein cholesterol acted asLDL-c were independent predictors of no-reflow in patients with acute coronary syndrome.(p<0.001 and p=0.017). AUC of calprotectin for predicting no-reflow were 0.898. The cut-off value of plasma calprotectin for no-reflow was 4748.77 ng/mL with a sensitivity of 0.95 and a specificity of 0.77. Conclusion Plasma calprotectin was associated with platelet activation and may act as an early predictionpredictive biomarker of no-reflow in patients with acute coronary syndrome.
- Open Access
- 9 June 2020
- Published by Springer Nature in Research Square
The Expression Profiles and Role of Circular RNA in Peripheral Blood of Myocardial Infarction Patients
Background: Myocardial infarction (MI) is one of the most widespread illnesses seriously harmful to human health. However, the mechanisms of its pathogenesis have not yet been completely proved. circRNA is one kind of non-coding RNA, recently published data suggests that circRNAs play a crucial role in heart diseases, but their expression profiles and role in MI patients are not yet completely defined. Methods: RNAs from peripheral blood samples were recruited for high-throughput RNA-seq analysis; The junction site part of circRNAs was confirmed by PCR with divergent primers; ROC curves were created to estimate the diagnostic value of circRNAs for MI; The expression level of circRNAs in clinical and cell samples were detected by RT-qPCR; MiRNA target site in exons of circRNA loci was verified by using miRanda, The binding sites of miRNA and mRNA were predicted by RNAhybrid; The regulatory roles of circSLC8A1 in cardiomyocytes were detected by TUNEL and Immunoblotting.Results: A total of 3862 circRNAs were detected to be remarkably changed, including 2738 circRNAs being upregulated, 1124 circRNAs being downregulated. circTMEM165, circUBAC2, circZNF609, circANKRD12, and circSLC8A1 were upregulated in MI and had closed loop structure. The results of ROC curves revealed that these five circRNAs had good sensitivity and specificity for MI diagnosis. Moreover, we created networks among circRNAs, miRNAs and mRNAs to predict the regulatory roles of circRNAs in MI. Besides that, we also demonstrated that circSLC8A1 contributed to cardiomyocytes apoptosis. Conclusions: In this study, we depicted the expression profiles of circular RNA in peripheral blood of myocardial infarction patients, revealed the five circRNAs may be very beneficial for MI diagnosis and regarded as possible biomarkers. Moreover, we also revealed that circSLC8A1 played a critical role in cardiomyocytes apoptosis.
- 9 June 2020
- Published by Springer Nature in Research Square
Open AccessThe Expression Profiles and Role of Circular RNA in Peripheral Blood of Myocardial Infarction Patients
Background: Myocardial infarction (MI) is one of the most widespread illnesses seriously harmful to human health. However, the mechanisms of its pathogenesis have not yet been completely proved. circRNA is one kind of non-coding RNA, recently published data suggests that circRNAs play a crucial role in heart diseases, but their expression profiles and role in MI patients are not yet completely defined. Methods: RNAs from peripheral blood samples were recruited for high-throughput RNA-seq analysis; The junction site part of circRNAs was confirmed by PCR with divergent primers; ROC curves were created to estimate the diagnostic value of circRNAs for MI; The expression level of circRNAs in clinical and cell samples were detected by RT-qPCR; MiRNA target site in exons of circRNA loci was verified by using miRanda, The binding sites of miRNA and mRNA were predicted by RNAhybrid; The regulatory roles of circSLC8A1 in cardiomyocytes were detected by TUNEL and Immunoblotting.Results: A total of 3862 circRNAs were detected to be remarkably changed, including 2738 circRNAs being upregulated, 1124 circRNAs being downregulated. circTMEM165, circUBAC2, circZNF609, circANKRD12, and circSLC8A1 were upregulated in MI and had closed loop structure. The results of ROC curves revealed that these five circRNAs had good sensitivity and specificity for MI diagnosis. Moreover, we created networks among circRNAs, miRNAs and mRNAs to predict the regulatory roles of circRNAs in MI. Besides that, we also demonstrated that circSLC8A1 contributed to cardiomyocytes apoptosis. Conclusions: In this study, we depicted the expression profiles of circular RNA in peripheral blood of myocardial infarction patients, revealed the five circRNAs may be very beneficial for MI diagnosis and regarded as possible biomarkers. Moreover, we also revealed that circSLC8A1 played a critical role in cardiomyocytes apoptosis.
- 1 June 2020
- Vol. 35 (6) , 541-552
The role of mitochondrial fusion and fission in the process of cardiac oxidative stress
Mitochondria are the energy suppliers in the cell and undergo constant fusion and fission to meet metabolic demand during the cell life cycle. Well-balanced mitochondrial dynamics are extremely important and necessary for cell survival as well as for tissue homeostasis. Cardiomyocytes contain large numbers of mitochondria to satisfy the high energy demand. It has been established that deregulated processes of mitochondrial dynamics play a major role in myocardial cell death. Currently, cardiac mitochondria' cell death pathways attract great attention in the cell biology and regenerative medicine fields. Importantly, mitochondria' dynamics are tightly linked to oxidative stress-induced cardiac damage. This review summarizes molecular mechanisms of mitochondrial fusion and fission processes and their potential roles in myocardial cell death triggered by oxidative stress. Advances in understanding the effect of both normal and abnormal mitochondria' dynamics on heart protection will lead to significant improvement of therapeutic discoveries.
- 1 June 2020
- Vol. 35 (6) , 541-552
The role of mitochondrial fusion and fission in the process of cardiac oxidative stress
Mitochondria are the energy suppliers in the cell and undergo constant fusion and fission to meet metabolic demand during the cell life cycle. Well-balanced mitochondrial dynamics are extremely important and necessary for cell survival as well as for tissue homeostasis. Cardiomyocytes contain large numbers of mitochondria to satisfy the high energy demand. It has been established that deregulated processes of mitochondrial dynamics play a major role in myocardial cell death. Currently, cardiac mitochondria' cell death pathways attract great attention in the cell biology and regenerative medicine fields. Importantly, mitochondria' dynamics are tightly linked to oxidative stress-induced cardiac damage. This review summarizes molecular mechanisms of mitochondrial fusion and fission processes and their potential roles in myocardial cell death triggered by oxidative stress. Advances in understanding the effect of both normal and abnormal mitochondria' dynamics on heart protection will lead to significant improvement of therapeutic discoveries.
- 12 May 2020
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 13 (4) , 572-583
Role of Circular RNAs in the Pathogenesis of Cardiovascular Disease
Circular RNAs (circRNAs) are single-strand covalently closed circular noncoding RNAs that are endogenous transcripts generated from linear precursor mRNA through a backsplicing mechanism. With the development of high-throughput sequencing technology, a number of circRNAs have been identified and proved to play key roles in various pathophysiological processes, such as metabolic diseases, cancers, and cardiovascular diseases. An increasing number of studies have shown that circRNAs are widely expressed in cardiac tissues and play important roles in the development of multiple cardiovascular diseases. Here, we review the current understanding of circRNA biogenesis and functions and the roles of circRNAs in cardiovascular diseases. We also highlight the molecular mechanisms underlying the role of circRNAs in the pathogenesis of cardiovascular diseases. A better understanding of the biological function of circRNAs in cardiovascular diseases will be helpful for the development of effective biomarkers for the diagnosis and treatment of these diseases.
- 12 May 2020
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 13 (4) , 572-583
Role of Circular RNAs in the Pathogenesis of Cardiovascular Disease
Circular RNAs (circRNAs) are single-strand covalently closed circular noncoding RNAs that are endogenous transcripts generated from linear precursor mRNA through a backsplicing mechanism. With the development of high-throughput sequencing technology, a number of circRNAs have been identified and proved to play key roles in various pathophysiological processes, such as metabolic diseases, cancers, and cardiovascular diseases. An increasing number of studies have shown that circRNAs are widely expressed in cardiac tissues and play important roles in the development of multiple cardiovascular diseases. Here, we review the current understanding of circRNA biogenesis and functions and the roles of circRNAs in cardiovascular diseases. We also highlight the molecular mechanisms underlying the role of circRNAs in the pathogenesis of cardiovascular diseases. A better understanding of the biological function of circRNAs in cardiovascular diseases will be helpful for the development of effective biomarkers for the diagnosis and treatment of these diseases.
- Open Access
- 27 April 2020
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 51 (10) , 999
Letter: the relationship between Helicobacter pylori and coronary heart disease
- 27 April 2020
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 51 (10) , 999
Open AccessLetter: the relationship between Helicobacter pylori and coronary heart disease
- Open Access
- 10 March 2020
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 11, 212
Circular RNA-Expression Profiling Reveals a Potential Role of Hsa_circ_0097435 in Heart Failure via Sponging Multiple MicroRNAs
Circular RNAs represent a new type of non-coding RNA molecules that influence the occurrence and development of various human diseases by sponging microRNAs, although their roles in heart failure have not been clarified. In this study, peripheral blood samples from 5 patients with heart failure and 4 healthy volunteers were analyzed by next-generation sequencing (NGS) to screen for differentially expressed Circular RNAs. Fifty-six differentially expressed Circular RNAs were identified, of which 29 were up-regulated and 27 were down-regulated. Dysregulated expression of 6 Circular RNAs was verified by quantitative polymerase chain reaction (PCR) analysis, and hsa_circ_0097435 expression was confirmed to be significantly up-regulated in 40 patients with heart failure. Further study with extracted exosomes showed that hsa_circ_0097435 expression was significantly higher in patients with heart failure. In cardiomyocytes, hsa_circ_0097435 was up-regulated after doxorubicin treatment, promoting cardiomyocyte apoptosis. Hsa_circ_0097435 overexpression promoted cardiomyocyte apoptosis, and silencing hsa_circ_0097435 inhibited apoptosis. Moreover, RNA-pulldown experiments and AGO2-immunoprecipitation experiments revealed that hsa_circ_0097435 potentially served a role in heart failure by sponging multiple microRNAs. Collectively, these results suggest that hsa_circ_0097435 can be used as a biological blood marker and revealed a new pathway involved in regulating myocardial cell injury. Our findings may provide a rational basis for developing new treatments for heart failure.
- 10 March 2020
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 11, 212
Open AccessCircular RNA-Expression Profiling Reveals a Potential Role of Hsa_circ_0097435 in Heart Failure via Sponging Multiple MicroRNAs
Circular RNAs represent a new type of non-coding RNA molecules that influence the occurrence and development of various human diseases by sponging microRNAs, although their roles in heart failure have not been clarified. In this study, peripheral blood samples from 5 patients with heart failure and 4 healthy volunteers were analyzed by next-generation sequencing (NGS) to screen for differentially expressed Circular RNAs. Fifty-six differentially expressed Circular RNAs were identified, of which 29 were up-regulated and 27 were down-regulated. Dysregulated expression of 6 Circular RNAs was verified by quantitative polymerase chain reaction (PCR) analysis, and hsa_circ_0097435 expression was confirmed to be significantly up-regulated in 40 patients with heart failure. Further study with extracted exosomes showed that hsa_circ_0097435 expression was significantly higher in patients with heart failure. In cardiomyocytes, hsa_circ_0097435 was up-regulated after doxorubicin treatment, promoting cardiomyocyte apoptosis. Hsa_circ_0097435 overexpression promoted cardiomyocyte apoptosis, and silencing hsa_circ_0097435 inhibited apoptosis. Moreover, RNA-pulldown experiments and AGO2-immunoprecipitation experiments revealed that hsa_circ_0097435 potentially served a role in heart failure by sponging multiple microRNAs. Collectively, these results suggest that hsa_circ_0097435 can be used as a biological blood marker and revealed a new pathway involved in regulating myocardial cell injury. Our findings may provide a rational basis for developing new treatments for heart failure.